|
1
|
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
N Engl J Med
|
2003
|
10.57
|
|
2
|
Coronary-artery bypass surgery in patients with left ventricular dysfunction.
|
N Engl J Med
|
2011
|
10.29
|
|
3
|
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
|
JAMA
|
2004
|
9.74
|
|
4
|
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
|
N Engl J Med
|
2004
|
9.13
|
|
5
|
Coronary bypass surgery with or without surgical ventricular reconstruction.
|
N Engl J Med
|
2009
|
7.71
|
|
6
|
Rhythm control versus rate control for atrial fibrillation and heart failure.
|
N Engl J Med
|
2008
|
6.17
|
|
7
|
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.
|
Circulation
|
2002
|
2.65
|
|
8
|
Identification of serum soluble ST2 receptor as a novel heart failure biomarker.
|
Circulation
|
2003
|
2.62
|
|
9
|
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
|
Ann Intern Med
|
2003
|
2.47
|
|
10
|
STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment.
|
J Am Coll Cardiol
|
2010
|
2.39
|
|
11
|
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
|
J Am Soc Nephrol
|
2005
|
2.25
|
|
12
|
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
|
Circulation
|
2002
|
2.20
|
|
13
|
Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
|
Circ Heart Fail
|
2012
|
1.48
|
|
14
|
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure.
|
Eur Heart J
|
2003
|
1.44
|
|
15
|
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial.
|
J Am Coll Cardiol
|
2003
|
1.39
|
|
16
|
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
|
Circulation
|
2004
|
1.33
|
|
17
|
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
|
Eur J Heart Fail
|
2006
|
1.22
|
|
18
|
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
|
Eur Heart J
|
2008
|
1.15
|
|
19
|
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.
|
Kidney Int Suppl
|
2004
|
1.12
|
|
20
|
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry.
|
Am Heart J
|
2006
|
1.10
|
|
21
|
Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure.
|
J Am Coll Cardiol
|
2002
|
1.07
|
|
22
|
Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial).
|
Am J Cardiol
|
2004
|
0.99
|
|
23
|
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2004
|
0.98
|
|
24
|
Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
|
J Card Fail
|
2007
|
0.96
|
|
25
|
Left ventricular assessment in myocardial infarction: the VALIANT registry.
|
Arch Intern Med
|
2005
|
0.92
|
|
26
|
The endothelin system and its role in acute myocardial infarction.
|
Can J Physiol Pharmacol
|
2003
|
0.90
|
|
27
|
Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.
|
Am J Physiol Heart Circ Physiol
|
2004
|
0.90
|
|
28
|
Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics.
|
Curr Opin Pharmacol
|
2002
|
0.89
|
|
29
|
Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
|
Am Heart J
|
2004
|
0.87
|
|
30
|
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy.
|
Am J Cardiol
|
2004
|
0.86
|
|
31
|
Value of the electrocardiogram in predicting left ventricular enlargement and dysfunction after myocardial infarction.
|
Am J Med
|
2003
|
0.85
|
|
32
|
Elevated mean arterial pressure in the ovariectomized rat was normalized by ET(A) receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis.
|
Br J Pharmacol
|
2002
|
0.84
|
|
33
|
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry.
|
Eur Heart J
|
2005
|
0.84
|
|
34
|
A forme fruste of Shone's anomaly in a 65 year-old patient.
|
Mcgill J Med
|
2008
|
0.82
|
|
35
|
Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale.
|
Can J Cardiol
|
2002
|
0.81
|
|
36
|
Circulating biomarkers in patients with heart failure and preserved ejection fraction.
|
Curr Heart Fail Rep
|
2013
|
0.81
|
|
37
|
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).
|
Am J Cardiol
|
2008
|
0.81
|
|
38
|
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
|
Am Heart J
|
2006
|
0.81
|
|
39
|
Characterization of myocardium, isolated cardiomyocytes, and blood pressure in WKHA and WKY rats.
|
Am J Physiol Heart Circ Physiol
|
2002
|
0.81
|
|
40
|
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
|
Ther Adv Cardiovasc Dis
|
2009
|
0.80
|
|
41
|
A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design.
|
Can J Cardiol
|
2007
|
0.79
|
|
42
|
Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
|
Can J Cardiol
|
2011
|
0.79
|
|
43
|
Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression.
|
Can J Physiol Pharmacol
|
2002
|
0.79
|
|
44
|
Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.
|
Am Heart J
|
2006
|
0.78
|
|
45
|
Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival.
|
Can J Physiol Pharmacol
|
2005
|
0.78
|
|
46
|
Genotype-dependent increase in plasma ACE activity after CABG is prevented by ACE inhibition.
|
Can J Cardiol
|
2003
|
0.77
|
|
47
|
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial).
|
Am J Cardiol
|
2005
|
0.77
|
|
48
|
AT1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post-MI.
|
Br J Pharmacol
|
2003
|
0.76
|
|
49
|
A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial.
|
Can J Cardiol
|
2008
|
0.76
|
|
50
|
The heart failure challenge: optimizing medical and surgical management.
|
Can J Cardiol
|
2006
|
0.75
|
|
51
|
Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats.
|
Can J Cardiol
|
2005
|
0.75
|
|
52
|
Effects of pre-, peri-, and postmyocardial infarction treatment with omapatrilat in rats: survival, arrhythmias, ventricular function, and remodeling.
|
Am J Physiol Heart Circ Physiol
|
2003
|
0.75
|
|
53
|
Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?
|
Can J Cardiol
|
2002
|
0.75
|
|
54
|
Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction.
|
Can J Physiol Pharmacol
|
2003
|
0.75
|
|
55
|
Vasopeptidase inhibition peri- and post-MI in Zucker insulin resistant rats: effect on MI size, arrhythmias, remodeling, function and fetal gene expression.
|
Cardiovasc Drugs Ther
|
2005
|
0.75
|
|
56
|
Effect of chronic treatment with bovine recombinant growth hormone on cardiac dysfunction and lesion progression in UM-X7.1 cardiomyopathic hamsters.
|
Endocrinology
|
2002
|
0.75
|
|
57
|
Forearm reactive hyperemic blood flow and arm-cranking exercise capacity in healthy and heart failure subjects.
|
J Card Fail
|
2002
|
0.75
|